Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr-Abl-inhibitor imatinib represents the first-line therapy against CML, almost 20-30% of patients develop chemotherapeutic resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salizzato, Valentina, Borgo, Christian, Cesaro, Luca, Pinna, Lorenzo A., Donella-Deana, Arianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951282/
https://www.ncbi.nlm.nih.gov/pubmed/26919095
http://dx.doi.org/10.18632/oncotarget.7569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951282/
https://www.ncbi.nlm.nih.gov/pubmed/26919095
http://dx.doi.org/10.18632/oncotarget.7569

Ejemplares similares